$1.15 Billion

argenx SE

Follow-on Offering

Bookrunner, February 2021

argenx SE

argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated therapies for the treatment of severe autoimmune diseases and cancer. The Company focuses on neuromuscular and hematology indications within its franchises. The Company’s most advanced product candidate, efgartigimod, is being developed for the treatment of the rare autoimmune disease, generalized myasthenia gravis (gMG). Efgartigimod is also being developed in three other indications: immune thrombocytopenia (ITP), pemphigus vulgaris (PV) and chronic demyelinating polyneuropathy (CIDP). The Company is also co-developing its second lead product candidate, cusatuzumab or ARGX-110, (targeting CD70), with its collaborator, Janssen, for the rare and aggressive hematological cancer acute myeloid leukemia (AML), as well as high-risk myelodysplastic syndrome (MDS).